ClinicalTrials.gg
Sign In

Smoldering Multiple Myeloma clinical trials

The registry lists 101 studies for Smoldering Multiple Myeloma across more than 10 countries. 34 are recruiting or about to start. 47 of them are mainly about Smoldering Multiple Myeloma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Smoldering Multiple Myeloma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting
30
Completed
26
Active, not recruiting
20
Terminated
13
Withdrawn
5
Not yet recruiting
3

Phase

Phase 2
45
Phase 1
10
Phase 3
6
Early Phase 1
4

Where

United States
71
Italy
10
France
9
United Kingdom
8
Spain
8
Netherlands
5

Who runs them

Dana-Farber Cancer Institute (10) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (5) · Janssen Research & Development, LLC (4) · City of Hope Medical Center (4) · Memorial Sloan Kettering Cancer Center (3) · Regeneron Pharmaceuticals (3) · PETHEMA Foundation (3)

What is being tested here

Drugs under test in Smoldering Multiple Myeloma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Linvoseltamab213
Iberdomide202
Dexamethasone107
Daratumumab125
Carfilzomib103
Isatuximab102
Curcumin102
Omega-3 fatty acid102
Propranolol101
Probiotic101

Drug classes tested here Proteasome inhibitors 1 open · Antimetabolites 4 · Immune checkpoint inhibitors 3 · Alkylating agents 3

Coming up

4phase 3 studies under way
15studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 30 Smoldering Multiple Myeloma studies recruiting now, 27 (90%) set no upper age limit and 1 (3%) stop at 75 or younger. 1 (3%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (13%) take healthy volunteers.

Recruiting studies that take each age, of 30
AgeWomenMen
101 (3%)1 (3%)
1828 (93%)28 (93%)
3029 (97%)29 (97%)
4030 (100%)30 (100%)
5030 (100%)30 (100%)
6530 (100%)30 (100%)
7530 (100%)30 (100%)
8528 (93%)28 (93%)

Across all 101 studies, recruiting or not: 7% stop at 75 or younger and 0% at 65; 5% take children; 0% are for women only and 0% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Smoldering Multiple Myeloma studies take

Of 26 phase 2 interventional studies under Smoldering Multiple Myeloma, half reached primary completion within 47 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 247 mo33–96 · 26 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 101. Browse all 101 → or search them.